Literature DB >> 17762557

Endoscopic evaluation and palliation of pancreatic adenocarcinoma: current and future options.

Nonthalee Pausawasdi1, James Scheiman.   

Abstract

PURPOSE OF REVIEW: To analyze the role of endoscopy in the diagnosis and treatment of pancreatic adenocarcinoma. New developments, including molecular analysis of endoscopic tissue samples and injection of antitumor agents, are discussed. RECENT
FINDINGS: Endoscopic ultrasound is superior to multidetector computed tomography for detection of smaller than 3-cm pancreatic tumors, and for T staging, while they are equivalent for nodal staging and assessment of resectability. Molecular analysis of endoscopic ultrasound-guided fine-needle aspiration samples has the potential to improve cancer detection. Placement of biliary self-expanding metal stents prior to Whipple resection appears to be an option to reduce stent obstruction and allow neo-adjuvant therapy. Endoscopic ultrasound-guided biliary drainage is a new approach to patients who failed to have a biliary stent placed by endoscopic retrograde cholangiopancreatography. Contrast-enhanced endoscopic ultrasound may be useful to differentiate focal inflammation from pancreatic carcinoma. Optical coherence tomography was shown to distinguish nonneoplastic from neoplastic main pancreatic duct tissue. Finally, endoscopic ultrasound-guided interstitial brachytherapy and injection of therapeutic agents into tumors have shown exciting preliminary results.
SUMMARY: Endoscopic approaches for diagnosis and palliation of pancreatic adenocarcinoma are rapidly expanding. These new techniques show promise in the diagnosis, staging, and treatment of pancreatic malignancy.

Entities:  

Mesh:

Year:  2007        PMID: 17762557     DOI: 10.1097/MOG.0b013e3282ba5713

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  3 in total

1.  Carcinoma pancreas.

Authors:  K J Singh; Ashwin Galagali; G Menon
Journal:  Med J Armed Forces India       Date:  2012-07

Review 2.  Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.

Authors:  David C Metz; Robert T Jensen
Journal:  Gastroenterology       Date:  2008-08-12       Impact factor: 22.682

3.  A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth.

Authors:  Ting Pan; Yiwen Zhang; Nan Zhou; Xin He; Cancan Chen; Liting Liang; Xiaobing Duan; Yingtong Lin; Kang Wu; Hui Zhang
Journal:  Oncotarget       Date:  2016-07-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.